Search
dolutegravir/lamivudine (Dovato)
Indications:
- treatment of treatment niave HIV1/AIDS
Contraindications:
- pregnancy
- hepatitis B coinfection
Dosage:
- once daily
Adverse effects:
- headache, diarrhea, nausea, insomnia, fatigue
- neural tube defects in fetus of pregnant women
Laboratory:
- HIV1 RNA < 500,000/mL for 1st line [2]
Notes:
- FDA-approved April 2019
General
antiretroviral combination
References
- FDA News Release. April 8, 2019
FDA approves first two-drug complete regimen for HIV-infected
patients who have never received antiretroviral treatment.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635526.htm
- Gandhi RT, Bedimo R, Hoy JF et al
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults.
2022 Recommendations of the International Antiviral Society - USA Panel.
JAMA. Published online December 1, 2022.
PMID: 36454551
https://jamanetwork.com/journals/jama/fullarticle/2799240
Component-of
abacavir/dolutegravir/lamivudine
Components
dolutegravir (Tivicay, DTG)
lamivudine (3TC, Epivir)